1.Pina-Sanchez P, Chavez-Gonzalez A, Ruiz-Tachiquin M, Vadillo E, Monroy-Garcia A, Montesinos JJ, et al. Cancer biology, epidemiology, and treatment in the 21st century: current status and future challenges from a biomedical perspective. Cancer Control. 2021;28:10732748211038735.
2.Ragothaman M, Yoo SY. Engineered phage-based cancer vaccines: current advances and future directions. Vaccines. 2023;11(5):919.
3.Yahya EB, Alqadhi AM. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sciences. 2021;269:119087.
4.Padma VV. An overview of targeted cancer therapy. BioMedicine. 2015;5:1-6.
5.Islam MS, Fan J, Pan F. The power of phages: revolutionizing cancer treatment. Frontiers in Oncology. 2023;13:1290296.
6.Abbaszadeh F, Leylabadlo HE, Alinezhad F, Feizi H, Mobed A, Baghbanijavid S, et al. Bacteriophages: cancer diagnosis, treatment, and future prospects. Journal of Pharmaceutical Investigation. 2021;51:23-34.
7.Yacoby I, Benhar I. Targeted filamentous bacteriophages as therapeutic agents. Expert opinion on drug delivery. 2008;5(3):321-9.
8.Zhang Y, Li C-X, Zhang X-Z. Bacteriophage-mediated modulation of microbiota for diseases treatment. Advanced Drug Delivery Reviews. 2021;176:113856.
9.Petrov G, Dymova M, Richter V. Bacteriophage-mediated cancer gene therapy. International Journal of Molecular Sciences. 2022;23(22):14245.
10.Hatfull GF, Hendrix RW. Bacteriophages and their genomes. Current opinion in virology. 2011;1(4):298-303.
11.Straus SK, Bo HE. Filamentous bacteriophage proteins and assembly. Virus Protein and Nucleoprotein Complexes. 2018:261-79.
12.Boeckaerts D, Stock M, Criel B, Gerstmans H, De Baets B, Briers Y. Predicting bacteriophage hosts based on sequences of annotated receptor-binding proteins. Scientific reports. 2021;11(1):1467.
13.Leiman PG, Shneider MM. Contractile tail machines of bacteriophages. Viral molecular machines. 2012:93-114.
14.Sciara G, Bebeacua C, Bron P, Tremblay D, Ortiz-Lombardia M, Lichière J, et al. Structure of lactococcal phage p2 baseplate and its mechanism of activation. Proceedings of the National Academy of Sciences. 2010;107(15):6852-7.
15.Szermer-Olearnik B, Drab M, Mąkosa M, Zembala M, Barbasz J, Dąbrowska K, et al. Aggregation/dispersion transitions of T4 phage triggered by environmental ion availability. Journal of nanobiotechnology. 2017;15:1-15.
16.Maghsoodi A, Chatterjee A, Andricioaei I, Perkins NC. How the phage T4 injection machinery works including energetics, forces, and dynamic pathway. Proceedings of the National Academy of Sciences. 2019;116(50):25097-105.
17.Olszak T, Latka A, Roszniowski B, Valvano MA, Drulis-Kawa Z. Phage life cycles behind bacterial biodiversity. Current medicinal chemistry. 2017;24(36):3987-4001.
18.Podlacha M, Grabowski Ł, Kosznik-Kawśnicka K, Zdrojewska K, Stasiłojć M, Węgrzyn G, et al. Interactions of bacteriophages with animal and human organisms—safety issues in the light of phage therapy. International journal of molecular sciences. 2021;22(16):8937.
19.Bloch H. Experimental investigation on the relationships between bacteriophages and malignant tumors. Arch Virol. 1940;1(2):481-96.
20.Bao Q, Li X, Han G, Zhu Y, Mao C, Yang M. Phage-based vaccines. Advanced Drug Delivery Reviews. 2019;145:40-56.
21.Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 2006;125(2):385-98.
22.Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404-7.
23.Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang Y, et al. Advances in the techniques and methodologies of cancer gene therapy. Discovery medicine. 2019;27(146):45-55.
24.Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, Soghomonyan S, et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proceedings of the National Academy of Sciences. 2008;105(11):4471-6.
25.Przystal JM, Umukoro E, Stoneham CA, Yata T, O’Neill K, Syed N, et al. Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage. Molecular oncology. 2013;7(1):55-66.
26.Smith TL, Yuan Z, Cardó-Vila M, Sanchez Claros C, Adem A, Cui M-H, et al. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proceedings of the National Academy of Sciences. 2016;113(9):2466-71.
27.Suwan K, Yata T, Waramit S, Przystal JM, Stoneham CA, Bentayebi K, et al. Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer. Proceedings of the National Academy of Sciences. 2019;116(37):18571-7.
28.Chongchai A, Waramit S, Suwan K, Al‐Bahrani M, Udomruk S, Phitak T, et al. Bacteriophage‐mediated therapy of chondrosarcoma by selective delivery of the tumor necrosis factor alpha (TNFα) gene. The FASEB Journal. 2021;35(5):e21487.
29.Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, et al. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. Journal of translational medicine. 2018;16:1-8.
30.de Vries CR, Chen Q, Demirdjian S, Kaber G, Khosravi A, Liu D, et al. Phages in vaccine design and immunity; mechanisms and mysteries. Current opinion in biotechnology. 2021;68:160-5.
31.Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 2011;1(1):31-45.
32.González-Mora A, Hernández-Pérez J, Iqbal HM, Rito-Palomares M, Benavides J. Bacteriophage-based vaccines: A potent approach for antigen delivery. Vaccines. 2020;8(3):504.
33.Palma M. Aspects of phage-based vaccines for protein and epitope immunization. Vaccines. 2023;11(2):436.
34.Asadi-Ghalehni M, Ghaemmaghami M, Klimka A, Javanmardi M, Navari M, Rasaee MJ. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study. Immunopharmacology and immunotoxicology. 2015;37(3):274-9.
35.Barati N, Razazan A, Nicastro J, Slavcev R, Arab A, Mosaffa F, et al. Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer letters. 2018;424:109-16.
36.Yin Z, Wu X, Kaczanowska K, Sungsuwan S, Comellas Aragones M, Pett C, et al. Antitumor humoral and T cell responses by mucin-1 conjugates of bacteriophage Qβ in wild-type mice. ACS chemical biology. 2018;13(6):1668-76.
37.Adhya S, Merril CR, Biswas B. Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harbor perspectives in medicine. 2014;4(1):a012518.
38.Binétruy‐Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis. The EMBO journal. 2000.
39.Ren S, Zuo S, Zhao M, Wang X, Wang X, Chen Y, et al. Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine. 2011;29(34):5802-11.
40.    Hurwitz H. Integrating the anti–VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clinical colorectal cancer. 2004;4:S62-S8.
41.Yavari B, Mahjub R, Saidijam M, Raigani M, Soleimani M. The potential use of peptides in cancer treatment. Current Protein and Peptide Science. 2018;19(8):759-70.
42.Wang A, Cui M, Qu H, Di J, Wang Z, Xing J, et al. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab. Oncotarget. 2016;7(46):75293.
43.Arab A, Nicastro J, Slavcev R, Razazan A, Barati N, Nikpoor AR, et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunologic research. 2018;66:200-6.
44.Hobernik D, Bros M. DNA vaccines—how far from clinical use? International journal of molecular sciences. 2018;19(11):3605.
45.Bazan J, Całkosiński I, Gamian A. Phage display—A powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Human vaccines & immunotherapeutics. 2012;8(12):1817-28.
46.Ghaemi A, Soleimanjahi H, Gill P, Hassan ZM, Razeghi S, Fazeli M, et al. Protection of mice by a λ-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology. 2011;54(3):105-12.
47.Bartolacci C, Andreani C, Curcio C, Occhipinti S, Massaccesi L, Giovarelli M, et al. Phage-based anti-HER2 vaccination can circumvent immune tolerance against breast cancer. Cancer Immunology Research. 2018;6(12):1486-98.
48.Thomas BS, Nishikawa S, Ito K, Chopra P, Sharma N, Evans DH, et al. Peptide vaccination is superior to genetic vaccination using a recombineered bacteriophage λ subunit vaccine. Vaccine. 2012;30(6):998-1008.
49.Ye X, Liu Z, Hemida MG, Yang D. Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA. PLoS one. 2011;6(6):e21215.
50.Ghosh D, Peng X, Leal J, Mohanty RP. Peptides as drug delivery vehicles across biological barriers. Journal of pharmaceutical investigation. 2018;48:89-111.
51.Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, et al. Targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Molecular Cancer Research. 2010;8(2):135-44.
52.Fukuta T, Asai T, Kiyokawa Y, Nakada T, Bessyo-Hirashima K, Fukaya N, et al. Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells. International Journal of Pharmaceutics. 2017;524(1-2):364-72.
53.Cai X-M, Xie H-L, Liu M-Z, Zha X-L. Inhibition of cell growth and invasion by epidermal growth factor-targeted phagemid particles carrying siRNA against focal adhesion kinase in the presence of hydroxycamptothecin. BMC biotechnology. 2008;8:1-7.
54.Yi H, Ghosh D, Ham M-H, Qi J, Barone PW, Strano MS, et al. M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors. Nano letters. 2012;12(3):1176-83.
55.Cohen BA, Bergkvist M. Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids. Journal of Photochemistry and Photobiology B: Biology. 2013;121:67-74.
56.Gandra N, Abbineni G, Qu X, Huai Y, Wang L, Mao C. Bacteriophage bionanowire as a carrier for both cancer-targeting peptides and photosensitizers and its use in selective cancer cell killing by photodynamic therapy. Small (Weinheim an der Bergstrasse, Germany). 2013;9(2):215.
57.Dong X, Pan P, Zheng D-W, Bao P, Zeng X, Zhang X-Z. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. Science Advances. 2020;6(20):eaba1590.
58.Maji M, Mazumder S, Bhattacharya S, Choudhury ST, Sabur A, Shadab M, et al. A lipid based antigen delivery system efficiently facilitates MHC class-I antigen presentation in dendritic cells to stimulate CD8+ T cells. Scientific reports. 2016;6(1):27206.
59.Wan Y, Wu Y, Bian J, Wang X, Zhou W, Jia Z, et al. Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine. Vaccine. 2001;19(20-22):2918-23.
60.Eriksson F, Tsagozis P, Lundberg K, Parsa R, Mangsbo SM, Persson MA, et al. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. The Journal of Immunology. 2009;182(5):3105-11.
61.Roehnisch T, Then C, Nagel W, Blumenthal C, Braciak T, Donzeau M, et al. Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. Journal of translational medicine. 2014;12:1-11.
62.Wang H, Yang Y, Xu Y, Chen Y, Zhang W, Liu T, et al. Phage-based delivery systems: engineering, applications, and challenges in nanomedicines. Journal of Nanobiotechnology. 2024;22(1):365.
63.Zalewska-Piątek B. Phage therapy—challenges, opportunities and future prospects. Pharmaceuticals. 2023;16(12):1638.
64.Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y, et al. A Comprehensive Review on Phage Therapy and Phage-Based Drug Development. Antibiotics. 2024;13(9):870.
65.Li XT, Peng SY, Feng SM, Bao TY, Li SZ, Li SY. Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy. Small. 2024;20(7):2307111.
66.Rehman S, Ali Z, Khan M, Bostan N, Naseem S. The dawn of phage therapy. Reviews in medical virology. 2019;29(4):e2041.
67.Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J. Current challenges and future opportunities of phage therapy. FEMS microbiology reviews. 2020;44(6):684-700.